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TetherinVpu enhances HIV-1 release by suppressing CD317-mediated tethering of virions to the cell surface. In HeLa H1
cells, Vpu(+) infection produces signiﬁcant amounts of tethered virions, although efﬁcient virus release requires
Vpu.We have analyzedmembrane targeting and assembly of newly synthesized Gag in infectedHeLaH1 cells by
quantitative pulse-chase assays in both Vpu(+) andΔVpu virus backgrounds and in the presence and absence of
CD317. Our results show that formation of tethered virions precedes release of viruses to the culture medium in
the Vpu(+) infection, and CD317 knockdown reduces tethering in both Vpu(+) and ΔVpu virus backgrounds.
Signiﬁcantly, our results indicate that tetheredVpu(+) viruses represent precursors for extracellular viruses, and
Vpu thus appears to reverse tethering in HeLa H1 cells after budding.f Zurich, Institute of Molecular
rland. Fax: +41 44 6356822.
. Suomalainen).
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Progeny virions of human immunodeﬁciency virus type 1 (HIV-1)
assemble at the plasma membrane (PM) of the infected cell (Deneka
et al., 2007; Finzi et al., 2007; Hübner et al., 2009; Ivanchenko et al.,
2009; Jouvenet et al., 2008; Jouvenet et al., 2006; Welsch et al., 2007).
The structural framework of the internal virion core is formed by the
viral core protein precursor Gag (Pr55Gag). Gag proteins are
synthesized on free polysomes in the cytosol and targeted to the PM
posttranslationally. Pr55Gag binds to the cytoplasmic leaﬂet of the PM
via an amino-terminal dual motif that consists of a myristic acid
modiﬁcation and a cluster of basic residues (Bryant and Ratner, 1990;
Ono and Freed, 1999; Zhou et al., 1994). The HIV-1 core structure is
formed at the cell surface, concomitantly with the budding process.
The assembly and budding event activates viral protease present in
minor core component, the Gag-Pol precursor (Kaplan et al., 1994).
The protease cleaves Pr55Gag into matrix, capsid (CA/p24), nucleo-
capsid, and p6 proteins, as well as two small spacer peptides.
Although viral core precursors (Gag, or Gag and Gag/Pol) assemble
into extracellular enveloped virus-like particles (VLPs) in the absence
of other virus components (Gheysen et al., 1989), virus release from
certain restrictive cell types, such as HeLa, Jurkat, and peripheral blood
mononuclear cells, is more efﬁcient if core components are expressed
together with the viral accessory protein Vpu (Göttlinger et al., 1993;
Klimkait et al., 1990; Neil et al., 2007). Vpu enhances virus releasefrom these restrictive cell types by counteracting a host cell factor
CD317/BST2/HM1.24/tetherin (referred to as CD317 in this work)
(Neil et al., 2008; Neil et al., 2007; van Damme et al., 2008). In the
absence of Vpu, progeny virions form at the PM of restrictive cells, but
the newly formed virions remain attached to the cell surface by
protein tethers formed by homodimers or higher-order oligomers of
CD317 (Hammonds et al., 2010; Perez-Caballero et al., 2009). The
tethered ΔVpu viruses can be released from restrictive cells by
protease treatment of intact cells (Neil et al., 2007). Antivirus activity
of CD317 is not limited to HIV-1. The protein inhibits release of many
different retroviruses and also viruses belonging to the families
Arenaviridae and Filoviridae (Jouvenet et al., 2009; Kaletsky et al.,
2009; Sakuma et al., 2009), as well as Kaposi's sarcoma-associated
herpesvirus (Mansouri et al., 2009). CD317 is a protein with an
unusual topology, since it has both an N-terminal transmembrane
domain and a C-terminal glycosyl-phosphatidylinositol (GPI) anchor,
and an extracellular domain capable of forming a disulﬁde-linked
coiled coil structure (Hinz et al., 2010). Both of themembrane anchors
as well as the extracellular disulﬁde-linked coiled coil are needed for
antiviral activity against HIV-1 (Andrew et al., 2009; Gofﬁnet et al.,
2009; Hinz et al., 2010; Iwabu et al., 2009; Perez-Caballero et al.,
2009). Apparently, only the overall conﬁguration of CD317 is
important for its antiviral activity, since an artiﬁcially constructed
CD317-like protein with no sequence homology to CD317 restricts
release of HIV-1 if the protein is incorporated into the envelope of the
budding virus particle (Perez-Caballero et al., 2009). The exact
mechanism by which CD317 tethers newly formed HIV-1 virions to
the cell surface, or the molecular mechanism by which Vpu counter-
acts CD317, is still unclear. CD317 can inﬁltrate the forming HIV-1
envelope (Fitzpatrick et al., 2010; Habermann et al., 2010; Hammonds
et al., 2010; Perez-Caballero et al., 2009), and Vpu-mediated exclusion
of CD317 from virus assembly/budding sites could be sufﬁcient to
neutralize antiviral activity of CD317. Indeed, several reports have
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different cell lines, as well as cause decline in steady-state levels of
CD317 (Andrew et al., 2009; Douglas et al., 2009; Gofﬁnet et al., 2009;
Gupta et al., 2009; Habermann et al., 2010; Mangeat et al., 2009;
McNatt et al., 2009; Mitchell et al., 2009; Rong et al., 2009; Sato et al.,
2009; Schindler et al., 2010; van Damme et al., 2008). However, two
recent reports indicate that CD317 is found in both Vpu(+) and ΔVpu
virions (Fitzpatrick et al., 2010; Habermann et al., 2010). Furthermore,
Vpu enhances virus release from infected CEMx174 and H9 cells
without causing down-regulation of cell surface CD317 (Miyagi et al.,
2009).
In the present study, we have used quantitative pulse-chase assays
to analyze the effects of Vpu and CD317 on membrane targeting and
incorporation of newly synthesized Pr55Gag into virions in infected
HeLa H1 cells. These cells produce considerable amounts of surface-
tethered HIV-1 particles even when Vpu is expressed in the infected
cell (Harila et al., 2006), and the amount of tethered viruses could be
reduced by knockdown of CD317 in both Vpu(+) and ΔVpu virus
backgrounds. Surprisingly, our data suggest that tethering is an
intermediate step in the release of Vpu(+) virions.Fig. 1. Comparison of Vpu(+) and ΔVpu virus infections. (A) Labeled Gag-derived bands are
H1 cells. NL4-3(ΔEnv)-infected cells were metabolically labeled with [35S]methionine for 3
particulate fraction of culture medium (=constitutively released VLPs; lane 2), anti-CA
immunoprecipitation of the particulate fraction of culture medium (lane 4). Lanes 3 and 5 ar
Photoshop to better visualize the Pr55Gag and its early processing intermediates which were
p24/25 are shown on the left. (B) Infected HeLa H1 cells were pulsed for 30 min and chased
(=const. VLPs, or constitutively released VLPs), virus particles released from cells after tryps
trypsin treatment (=membr.). Equal aliquots of the different fractions were analyzed by SDS
−Vpu indicates NL4-3(ΔVpu/ΔEnv) infection. The ﬁrst lanes (noninf.) show a membrane fra
left. Quantitation of p24/p25 bands (arbitrary values) are shown at the bottom of panels. (
released VLPs-fractions at the 3-h chase point. The values represent mean values from three
fraction of NL4-3(ΔVpu/ΔEnv) homogenates represents protein present in internal memb
Trypsin-treated cells were coated with silica beads before homogenization, and cell homoge
the gel is shown.Results
Membrane targeting and assembly of newly synthesized Gag in HeLa H1
cells infected with Vpu(+) or Vpu-deleted HIV-1
Vpu is required for efﬁcient release of progeny HIV-1 virions from
infected HeLa H1 cells, but signiﬁcant amounts of produced virions
remain tethered to the cell surface even if Vpu is expressed in the
infected cells (e.g. EM analysis in Harila et al., 2006). Fig. 1 shows a
comparison of Vpu(+) and ΔVpu virus infections in HeLa H1 cells
[NL4-3(ΔEnv) and NL4-3(ΔVpu/ΔEnv), respectively; both viruses are
lacking the env gene]. Cells were infected with VSV-G-pseudotyped
Vpu(+) or ΔVpu virus at the sameMOI (~5 infectious units/cell), and
at 24 h after infection, cells were metabolically labeled with [35S]
methionine for 30 min and chased for up to 3 h. These time points
were chosen because pilot experiments indicated that virus produc-
tion had reached maximal level at 24 h after infection, and kinetic
analysis indicated that ~80% of maximal incorporation of labeled Gag
into VLPs was achieved during the ﬁrst 3 h of chase (data not shown).
After chase, the sample was divided into three fractions: (1) VLPsmajor bands in the total membrane and particulate medium fractions of infected HeLa
0 min and chased for 3 h. Shown are total membrane fraction of cell extracts (lane 1),
immunoprecipitation of the total membrane fraction (lanes 3 and 5), and anti-CA
e otherwise identical except that lane 5 has been enhanced and contrasted differently in
not as efﬁciently immunoprecipitated by the antibody as p24. Positions of Pr55Gag and
for the indicated times. Shown are virus particles recovered from culture supernatants
in-treatment (=tethered VLPs), and the amount of Gag remaining in membranes after
–PAGEwithout prior immunoprecipitation. +Vpu indicates NL4-3(ΔEnv) infection, and
ction isolated from noninfected cells. Positions of Pr55Gag and p24/25 are shown on the
C) Percentage of labeled p24/p25 in the membrane-, tethered VLPs- and constitutively
independent experiments with standard deviations shown. (D) p24 in the membrane
ranes. NL4-3(ΔVpu/ΔEnv)-infected cells were pulsed for 30 min and chased for 3 h.
nates were fractionated into PM and internal membranes (I). Only the p24/p25 part of
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to the cell surface (=VLPs released after trypsin treatment of cells),
and (3) membrane-associated material. Fractions 1 and 2 were
puriﬁed by ultracentrifugation through a 20% sucrose cushion,
whereas fraction 3 was isolated from postnuclear supernatants of
cell homogenates prepared after trypsin treatment of cells. The
postnuclear supernatants were fractionated on a Nycodenz step
gradient to separate membranes from cytosol. Equal aliquots of the
three fractions were analyzed by gel electrophoresis. As shown in
Fig. 1A, labeled Gag proteins are major proteins in the membrane
fraction of infected HeLa H1 cells when MOI ~5 infectious units/cell is
used, and thus the VLP and membrane fractions can be analyzed
without prior immunoprecipitation. The upper panel in Fig. 1B shows
the analysis of Vpu(+) infection. The precursor Pr55Gag, and a
partially processed intermediate of Pr55Gag, could be identiﬁed in the
membrane fraction after 30 min of chase. The amounts of these Gag
forms were reduced at later time points, and labeled p24 became
evident in the membrane fraction. Interestingly, labeled p24
accumulated in tethered VLPs more rapidly than in constitutively
released VLPs; the amount of labeled p24 in tethered VLPs leveled off
after 1.5 h of chase, whereas there still was a clear increase in the
amount of labeled p24 in constitutively released VLPs between 1.5-
and 3-h chase. Quantitations from three independent experiments
indicated that the Vpu(+) infection had roughly equal amounts of
tethered vs. constitutively released VLPs at the 3-h chase point
(Fig. 1C). The lower panel in Fig. 1B shows analysis of NL4-3(ΔVpu/
ΔEnv)-infected cells. Efﬁcient constitutive release of virus particles
from HeLa H1 cells is dependent on Vpu, and only trace amounts of
labeled p24 were recovered from the culture supernatants of NL4-3
(ΔVpu/ΔEnv)-infected cells: quantitation from three independent
experiments showed that constitutively released VLPs harbored only
~4% of total labeled p24 at the 3-h chase point (Fig. 1C). Tethered
VLPs with labeled p24 formed with similar kinetics as in the NL4-3
(ΔEnv) infection. The amounts of labeled Gag precursors in the
membrane fractions after 30-min chase were similar in the NL4-3
(ΔEnv) and NL4-3(ΔVpu/ΔEnv) infections, but at later time points,
more labeled p24 was seen in the membrane fractions of NL4-3
(ΔVpu/ΔEnv)-infected cells than in cells infected with the Vpu(+)
virus. This most likely reﬂected endocytosis of tethered VLPs in the
ΔVpu background (Harila et al., 2006; Harila et al., 2007), since if the
plasma membrane of trypsin-treated cells (3 h chase point) was
coated with silica beads prior to homogenization, and the homog-
enate was fractionated on Nycodenz gradient into silica-coated
plasma membrane and uncoated internal membrane fractions
(Harila et al., 2006), the majority of trypsin-resistant cell-associated
labeled p24 fractionated with internal membranes (Fig. 1D). Endo-
cytosis of tethered VLPs would also explain the apparent decrease of
labeled p24 in tethered VLPs between the 1.5-h and 3-h chase points
in the ΔVpu infection (Fig. 1B). However, the efﬁciency of
endocytosis of tethered VLPs was somewhat different in repetitive
experiments, as shown by the variations in the relative amounts of
labeled p24 in membrane vs. tethered VLPs fractions in ΔVpu
infection at the 3-h chase point (Fig. 1C). The total amount of labeled
p24 (i.e., sum of p24 in the membrane fraction, tethered VLPs, and
constitutively released VLPs) can be used as a rough estimate for the
overall assembly efﬁciency, since processing of Pr55Gag is closely
linked to budding (Kaplan et al., 1994). In the experiment shown
in Fig. 1B, the total amount of labeled p24 at the 3-h chase point in
NL4-3(ΔVpu/ΔEnv)-infected cells was 58% of that of the Vpu(+)
infection. However, if crude cell homogenates were used for
membrane isolation instead of postnuclear supernatants, total p24
in NL4-3(ΔVpu/ΔEnv)-infected cells after 3 h of chase was over 80%
of the equivalent p24 of NL4-3(ΔEnv) infection (data not shown).
This difference most likely reﬂects loss of the PM and/or internal
membranes into the pellet fraction in the centrifugation step used to
prepare the postnuclear supernatants.Knockdown of CD317 reduces tethering of both Vpu(+) and
ΔVpu virions
We next tested the effect of CD317-speciﬁc siRNAs to determine
whether tethering of progeny VLPs to the cell surface in Vpu(+) and
ΔVpu virus backgrounds was due to CD317. Immunoﬂuorescence
staining of siRNA- and mock-transfected cells (=cells treated only
with the transfection reagent) with anti-CD317 antibody indicated
that the CD317 siRNAs effectively reduced intracellular amounts of
CD317 (Fig. 2A). In the experiment shown in Fig. 2B, cells were
transfected with CD317 siRNAs or mock-transfected, infected with
VSV-G-pseudotyped NL4-3(ΔVpu/ΔEnv) the following day, and
analyzed at 24 h after infection. The cells were metabolically labeled
for 30 min, and chased for 30 min, 2 h, or 3 h. Crude cell homogenates
were used for the isolation of membrane fraction. The CD317 siRNAs
dramatically increased constitutive release of VLPs fromNL4-3(ΔVpu/
ΔEnv)-infected cells and reduced the amounts of labeled p24 in
membrane fraction and tethered VLPs.
The effect of CD317 knockdown on virus production in NL4-3
(ΔEnv)-infected HeLa H1 cells is shown in Fig. 2C. The cells were
metabolically labeled for 30 min at 24 h after infection and chased for
3 h. The knockdown of CD317 decreased amounts of tethered VLPs in
the Vpu(+) virus background. This reduction in tethered VLPs was
speciﬁc toCD317 siRNAs since similar amountsof a control nontargeting
siRNA, siRNAs directed against CAML (calcium signal-modulating
cyclophilin ligand) or several other targeting siRNAs (e.g., siRNAs
against CD44, CD63, CD9; data not shown) did not reduce the amounts
of tethered VLPs in Vpu(+) infection. Quantitations from four different
Vpu(+) infection experiments indicated a statistically signiﬁcant
decrease in relative amounts of tethered VLPs in CD317 siRNA-treated
cells in comparison tomock-or control siRNA-treated cells (Fig. 2D). The
difference between mock- and control siRNA-treated cells was not
statistically signiﬁcant.
Tethered VLPs are precursors for constitutively released VLPs
Since labeled p24 appeared in tethered and constitutively released
VLPs with different kinetics (Fig. 1), this suggested that these two VLP
populations were either formed by different pathways or that
tethered VLPs represented precursors for constitutively released
VLPs. In Fig. 3, we have tested this latter possibility. Our objective
was to determine whether enzymatic removal of tethered VLPs would
compromise subsequent release of labeled p24 into culture medium.
NL4-3(ΔEnv)-infected cells were metabolically labeled for 30 min,
and treated with trypsin at the 1.5- or 2-h chase point to remove
tethered VLPs. Control cells on parallel plates received only a media
change. Cells were then incubated for further 2 h before constitutively
released and tethered VLPs were collected. To ascertain that virus
production was compared from similar numbers of cells, the levels of
glycerol aldehyde-3-phosphate dehydrogenase (GAPDH) in cell
extracts of trypsin-treated and control cells were analyzed on
Western blots, and used as a normalization factor for cell numbers
(data not shown). Fig. 3A shows the analysis of cells treated with
trypsin at the 2-h chase point. At this chase point, the cells had
considerable amounts of tethered VLPs. Control cells that received
only a change of culture medium at the 2-h chase point efﬁciently
released VLPs during next 2 h of chase. In contrast, very little labeled
p24 was found in constitutively released or tethered VLPs at the
4-h chase point in the sample that had been treated with trypsin at the
2-h chase point. In two separate experiments, the trypsin treatment at
the 1.5- or 2-h chase point (=experiment shown in Fig. 3A) reduced
subsequent constitutive release of VLPs by 77% or by 75%, respectively,
in comparison to control, nontreated cells. The sum of tethered and
constitutively released viruses from the trypsin-treated cells was ~16%–
18% of that of control cells in the two experiments. However, if the
amount of labeled p24 removed by trypsin at the 1.5- or 2-h chase point
Fig. 2. CD317 knockdown. (A) CD317 siRNAs efﬁciently reduce intracellular levels of CD317. Cells were either mock-transfected or transfected with CD317-speciﬁc siRNAs prior to
infection with NL4-3(ΔEnv). At 48 h after transfection and 24 h after infection cells were ﬁxed, permeabilized and stained with mouse polyclonal anti-CD317 antibodies and an
Alexa555-conjugated anti-mouse antibody. (B) HeLa H1 cells infected with ΔVpu virus. Cells were either mock-transfected or transfected with CD317-speciﬁc siRNAs prior to
infection with NL4-3(ΔVpu/ΔEnv). The cells were metabolically labeled for 30 min, chased for the indicated times, and analyzed as described in the legend for Fig. 1. (C) VLP
production from mock-, CD317 siRNA-, control nontargeting siRNA- and CAML siRNA-treated HeLa H1 cells infected with Vpu(+) virus. Cells were metabolically labeled for 30 min
and chased for 180 min. Mock and CD317 siRNA results are from the same experiment, whereas control and CAML siRNA results are from separate experiments. Percentage of labeled
p24/p25 in tethered VLPs is shown at the bottom of the panel. Only the p24/p25 part of the gel is shown. (D) Statistical analysis of virus production from mock-, control siRNA or
CD317 siRNA-transfected cells in Vpu(+) infection. Shown is the percentage of labeled p24/p25 in tethered VLPs at the 3-h chase point. The values represent mean values from four
independent experiments with standard deviations. p values are from Student's t test.
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trypsin-treated sample at the 4-h chasepointwas87%–89%of that of the
respective control samples. To verify that trypsin treatment did not
cause general inhibition of virus release, we performed trypsin
treatment after the 30-min pulse and chased cells for 2 h. As shown in
Fig. 3B, in this case, the trypsin-treated cells produced virus as efﬁciently
as control nontreated cells. In two separate experiments, the constitu-
tive virus release from cells treated with trypsin immediately after the
pulse was 112% or 98% of that of control cells, and the total amount of
labeled p24 in tethered VLPs and constitutively released VLPs of the
trypsin-treated cellswas 83% or 71% of that of control cells. Thus, trypsin
treatment of cells did not cause a general inhibition of virus release. The
trypsin-treated cells had 60%–78% less tethered VLPs than the control
cellswhen trypsin treatmentwasdone immediately after the pulse. This
wasmost likelydue to the fact that trypsin treatment removed tethering
factors fromtheplasmamembrane and2 hof chasewas too short a time
to effectively repopulate the cell surface with these factors. Suppression
of tethering after trypsin treatment was evident also in ΔVpu-
background, since if NL4-3(ΔVpu/ΔEnv)-infected cells were trypsin-treated after a 30-min pulse, and chased for 2 h, the cells efﬁciently
released VLPs into the culture medium (Fig. 3C). This effect was
observed in two separate experiments. In Fig. 3C, the sumof labeled p24
in tethered and constitutively released VLPs of the trypsin-treated cells
was 1.7-fold higher than that of control cells. The lower value of control
cells was most likely due to endocytosis of tethered VLPs. Taken
together, the results in Fig. 3 imply that tethered VLPs are precursors for
constitutively released VLPs, and that ‘tethering’ is an intermediate step
in the formation and release of Vpu(+) viruses.
Discussion
CD317/tetherin is an antiviral defense factor that has a capacity to
tether newly formed HIV-1 virions to the cell surface (Neil et al., 2008;
van Damme et al., 2008). These tethered virions can be released from
cell surface by treatment with a protease. Vpu counteracts this effect
of CD317/tetherin, and Vpu is needed for efﬁcient ‘constitutive’ virus
release from cells that express CD317, such as the HeLa H1 cells used
in the present study. Previous EM studies suggested that these cells
Fig. 3. Tethered (Vpu+)–VLPs are precursors for extracellular VLPs. (A) Removal of
tethered VLPs at the 2 h chase point signiﬁcantly reduces constitutive virus release
during the next 2 h of chase. NL4-3(ΔEnv)-infected HeLa H1 cells on three parallel
plates were metabolically labeled with [35S]methionine for 30 min, and chased for 2 h.
At the 2 h chase point, one plate was used to determine the amounts of constitutively
released and tethered VLPs at this time point (=2 h), whereas cells on the two
remaining plates either received a medium change (4 h/− trypsin) or were treated
with trypsin (4 h/+ trypsin) to remove tethered VLPs, and then chased for further 2 h.
At the end of this second 2-h chase period, the amounts of constitutively released and
tethered VLPs were again analyzed. Only the p24/p25 part of the gel is shown, and
quantiﬁcations of p24/p25 bands (arbitrary values) are shown at the bottom of the
panel. (B) Trypsin treatment does not cause general inhibition of virus release. NL4-3
(ΔEnv)-infected HeLa H1 cells were metabolically labeled with [35S]methionine for
30 min. After the pulse, cells were either treated with trypsin or not treated, and chased
for 2 h, and the amounts of constitutively released and tethered VLPs were analyzed.
(C) Trypsin treatment enhances constitutive virus release from NL4-3(ΔVpu/ΔEnv)-
infected HeLa H1 cells. Cells were metabolically labeled and analyzed as in B.
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expressed in the virus-producing cells (Harila et al., 2006), and this
was conﬁrmed by quantitative pulse-chase assays and subcellular
fractionations of the present study. We analyzed targeting of newly
synthesized Gag proteins to membranes in infected HeLa H1 cells and
compared the membrane targeting to formation of tethered and
constitutively released VLPs. The analyses were done in both Vpu(+)
and ΔVpu virus backgrounds [NL4-3(ΔEnv) and NL4-3(ΔVpu/ΔEnv)
infections, respectively]. Our results indicated that the tethered and
constitutively released VLPs of Vpu(+) infection formed with
different kinetics, whereas the amount of labeled tethered VLPs
reached maximal levels after about 1.5 h of chase, the amount of
labeled virions in the culture medium still increased after this chase
point. Tethered VLPs in the ΔVpu background formed with similar
kinetics as in the Vpu(+) infection, but virus release into the medium
was inefﬁcient in the absence of Vpu. Interestingly, when tethered
VLPs at the 2-h chase point were removed from NL4-3(ΔEnv)-
infected cells by trypsin, this dramatically reduced the amount of virus
released into the culturemedium during next 2 h of chase. In contrast,
control non-trypsin-treated cells efﬁciently accumulated virus into
the culture medium between 2 h and 4 h of chase. Furthermore, if
trypsin treatment was done immediately after the pulse, both NL4-3
(ΔEnv)- and NL4-3(ΔVpu/ΔEnv)-infected cells efﬁciently produced
labeled VLPs into the culture medium during the following 2 h of
chase, thus indicating that trypsin treatment in general was not
inhibitory for virus release. These results imply that tethered virions
in the Vpu(+) background represented precursors for extracellular
viruses and that tethering was an intermediate step in the release of
Vpu(+) virions to the culture medium. A reversible tethering
mechanism predicts a lag time for particle release after completed
assembly and budding. Indeed, such a lag time has been observed inlive analyses of HIV-1 particle formation (Ivanchenko et al., 2009),
although at present it is not known whether the lag time is due to a
budding-related phenomenon (e.g., membrane ﬁssion–reaction) or to
some postbudding event.
But what is the tethering mechanism in the Vpu(+) infection in
HeLa H1 cells? As discussed above, virus tethering in the ΔVpu-
background is mediated by CD317, and CD317 promotes virus
tethering by directly cross-linking newly formed virions to the cell
surface (Fitzpatrick et al., 2010; Hammonds et al., 2010; Perez-
Caballero et al., 2009). Tethering of ΔVpu virions to the cell surface of
infected HeLa H1 cells is similar to tethering ofΔVpu virions described
in other cells, since knockdown of CD317 in infected HeLa H1 cells
greatly augmented release of ΔVpu–VLPs into the culture medium.
The CD317 siRNAs also reduced the amount of tethered VLPs in the
Vpu(+) infection, and this reduction was speciﬁc for CD317 siRNAs
since several other targeting or nontargeting siRNAs that we have
tested have not given the same effect as the CD317-speciﬁc siRNA
pool used in the present study. This suggests that tethering of VLPs in
the Vpu(+) background is, directly or indirectly, CD317-mediated as
well. This is also supported by the observation that tethered VLPs
formed with similar kinetics in both Vpu(+) and ΔVpu virus
backgrounds. In the experimental setup used, we could not do the
control experiment to express siRNA-resistant CD317 in the knock-
down cells, because we have not yet found a transfection reagent that
would efﬁciently transfect plasmid DNA into HeLa H1 cells. Exactly
how CD317 tethers nascent HIV-1 particles to the cell surface, or how
Vpu counteracts CD317, is still unknown. Both the transmembrane
domain and the carboxy-terminal GPI anchor, as well as ability to
form homodimers are important for antiviral activity of CD317
(Andrew et al., 2009; Gofﬁnet et al., 2009; Hinz et al., 2010; Iwabu
et al., 2009; Perez-Caballero et al., 2009), but the conﬁguration of
CD317 in virus tethers is unclear. CD317 can be incorporated into the
forming HIV-1 envelope (Fitzpatrick et al., 2010; Habermann et al.,
2010; Hammonds et al., 2010; Perez-Caballero et al., 2009), and two
models have been proposed for CD317-mediated tethering mecha-
nism. One model postulates that ectodomain interactions between
virion- and plasma membrane-associated CD317 proteins form
protein tethers that keep newly formed virions attached to the PM,
whereas the other model predicts that the two membrane anchors of
CD317 partition into separate membranes during budding, i.e., one
end of CD317 becomes embedded in the donor plasmamembrane and
the other end in the virion envelope (e.g., Perez-Caballero et al., 2009).
Although recent structural analysis of CD317 indicated that the
protein is capable of adopting an extended rod-like conformation
compatible with the latter tethering model (Hinz et al., 2010), at
present there is no direct evidence for either model. For example,
Fitzpatrick et al. (2010) reported that enzymatic cleavage of GPI
anchors by phosphatidyl inositol-speciﬁc phospholipase C failed to
release tethered HIV-1 virions. Furthermore, EM studies have
identiﬁed long, linear ﬁlamentous strands between tethered viruses,
and these structures were decorated with anti-CD317 antibodies
(Hammonds et al., 2010). This implies that multiple CD317 proteins
might form the tethering structures. Apparently, CD317 does not need
any speciﬁc cofactors to inhibit HIV-1 release, since an artiﬁcially
constructed CD317-like protein with no sequence homology to
CD317, but with similar overall structure has been shown to be
capable of limiting HIV-1 release (Perez-Caballero et al., 2009). In
contrast, the CD317-mediated tethering mechanism of human T-cell
leukemia virus type 1 (HTLV-1) is more complex since CD317 is part
of a multiprotein bioﬁlm-like structure that tethers HTLV-1 viruses to
the cell surface (Pais-Correia et al., 2010). Vpu downregulates cell
surface expression of CD317 in many cell types (Douglas et al., 2009;
Gofﬁnet et al., 2009; Gupta et al., 2009; Mangeat et al., 2009; Rong
et al., 2009; Sato et al., 2009; van Damme et al., 2008), and this has led
to the hypothesis that Vpu inhibits inﬁltration of virus particles by
CD317 via lowering concentration of CD317 at the plasmamembrane.
294 A. Karetnikov, M. Suomalainen / Virology 407 (2010) 289–295However, two recent studies indicated that Vpu(+) virions are not
devoid of CD317. In fact, one of these studies found an apparent
enrichment for CD317 in both Vpu(+) and ΔVpu virion envelopes in
comparison to the PM, and only minor differences in the amounts of
CD317 between the two virus populations (Habermann et al., 2010),
whereas the other study found that lack of Vpu leads to about 2-fold
higher concentration of CD317 in the virion envelope (Fitzpatrick
et al., 2010). Thus, simple exclusion of CD317 from virus budding sites
does not seem to fully account for Vpu-mediated suppression of
antiviral activity of CD317. Of note, our ﬂow cytometry analyses have
indicated that Vpu reduced CD317 at the cell surface by 46% in
infected HeLa H1 cells, whereas cells infected with ΔVpu virus had
surface amounts of CD317 comparable to those of noninfected cells
(data not shown). Exactly how important the down-modulation of
CD317 from the cell surface is for enhancement of virus release by Vpu
remains to be determined since in certain cell types Vpu appears to
promote virus release without downregulating the surface CD317
(Miyagi et al., 2009). Our results suggest a new viewpoint into the
Vpu-mediated suppression of CD317, namely that Vpu might, directly
or indirectly, resolve tethered particles after budding. However,
further studies are needed to substantiate this hypothesis, and to
formulate a model how this putative Vpu-mediated postbudding
release of tethered VLPs could function.
Materials and methods
Cell culture, viruses, and plasmid constructs
HeLa H1 and 293T cells were cultured as previously described
(Harila et al., 2006; Holm et al., 2003). Production of vesicular stomatitis
virus (VSV)–G-protein-pseudotyped infectious recombinant HIV-1 in
293T cells has been previously described (Harila et al., 2006). Titers of
virus stocks were determined by immunoﬂuorescence staining of
infected HeLaH1 cells (anti-CA staining at 24 h after infection). Plasmid
pNL4-3(ΔVpu/ΔEnv) has been previously described (Harila et al.,
2007). Plasmid pNL4-3(ΔEnv) was constructed by replacing the 2680-
bp SalI–BamHI fragment of pNL4-3 (Adachi et al., 1986) with the
equivalent 2100-bpSalI–BamHI fragmentof pNL4-3(Gag/ΔEnv) (Harila
et al., 2006).
Subcellular fractionations
HeLa H1 cells on 10-cm plates were infected with VSV-G-
pseudotyped recombinant HIV-1 (about 5 infectious units/cell). At
~24 h after infection, cells were metabolically labeled with [35S]
methionine for 30 min and chased for various times as previously
described (Holm et al., 2003). After the chase, cell culture super-
natants were collected, and after removal of cell debris by 200×g
centrifugation, the cleared supernatants were layered onto a 20%
sucrose cushion (wt./vol., in 25 mM HEPES pH 7.4, 150 mM NaCl,
2 mM MgCl2), and centrifuged at 100,000×g for 60 min to obtain
pellets, which represented constitutively released VLPs. To collect the
tethered VLPs, cells were brieﬂy washed with phosphate-buffered
saline containing 0.02% EDTA after harvesting culture supernatants
and treated with trypsin (0.5 mg/ml) at 37 °C for 8 min. The reaction
was stopped by adding culture medium containing 7% fetal bovine
serum, cells were pelleted and VLPs from the culture supernatants
were concentrated through sucrose as described above. The cell
pellets from the trypsin treatment were washed once with a buffer
containing 25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM MgCl2, and
homogenized with a tight-ﬁtting Dounce homogenizer in the wash
buffer supplemented with additional 2 mM MgCl2, 20 μg of phenyl-
methylsulfonyl ﬂuoride, 1 μg of CLAP inhibitor mix (chymostatin,
leupeptin, aprotinin, and pepstatin), and 100 μg of soybean trypsin
inhibitor per ml. Either postnuclear supernatants or crude cell
homogenates (the latter treated with 1.2 mg/ml DNase I for 30 minon ice) were used for isolation of membranes. The postnuclear
supernatants or DNase I-treated crude cell homogenates were mixed
with 100% Nycodenz solution (Axis-Shield PoC) to give a ﬁnal 60%
Nycodenz concentration. The samplewas overlaidwith 50% Nycodenz
and a buffer solution containing 25 mM HEPES pH 7.4, 150 mM NaCl,
and 1 mM EDTA. The gradient was centrifuged at 100,000×g for
60 min, and the total membrane fraction at the 50% Nycodenz-buffer
interphase (=membrane-associated material) was collected. Equal
aliquots of the membrane-associated material, tethered VLPs, and
constitutively released VLPs were analyzed by SDS–polyacrylamide
gel electrophoresis (SDS–PAGE). The labeled Gag bands in membrane
fractions and VLPs were quantiﬁed by Fuji BAS-1500 phosphoimager
by subtracting a background value (=equal area from above or below
the Gag band) from the value measured for Gag bands. The identity of
Gag-derived bands in membrane and VLP fractions was veriﬁed by
immunoprecipitation using a polyclonal rabbit anti-CA antibody
(provided by Jorma Hinkula, Linkoping University, Linkoping, Sweden).
Aliquots of postnuclear supernatants of cell extracts were analyzed by
Western blotting using a polyclonal anti-glyceraldehyde-3-phosphate
dehydrogenase antibody (FL-335; Santa Cruz Biotechnology, Inc.) to
ensure that samples to be compared contained similar numbers of cells.
Silica coating of PM and separation of PM and internal membranes
were carried out as previously described (Harila et al., 2006).
RNAi
Small interfering RNAs (siRNAs) were transfected into HeLa H1
cells (~40%–50% conﬂuent cell cultures on 10-cm plates) by using
siLentFect (BioRad; 20 μl per 10-cm plate) in accordance with the
manufacturer's instructions. At about 22 h after transfection, cells
were infected and analyzed at 24 h after infection. For CD317 or
CAML knockdowns, HeLa H1 cells were transfected with siGENOME
ON-TARGET plus SMARTpool human CD317- or CAML-speciﬁc
siRNAs (Dharmacon; 120 pmol per 10-cm plate). Control cells were
treated with the transfection reagent alone or with a control
nontargeting siRNA (Harila et al., 2006). Efﬁciency of CD317
knockdown was checked by staining paraformaldehyde-ﬁxed and
saponin-permeabilized mock- or siRNA-treated cells with a mouse
polyclonal anti-CD317 antibody (B02P: Abnova) and an Alexa555-
conjugated goat anti-mouse antibody at 48 h after transfection. The
images were acquired with Zeiss Axioplan 2 microscope and Wasabi
software and processed in Photoshop.
Statistical analyses
Error bars in all the graphs represent the standard deviation of the
mean with p values from Student's t-tests.
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